Brain metastases - Pipeline Insight, 2024

This “Brain metastases- Pipeline Insight, 2024” report provides comprehensive insights about 40+ companies and 45+ pipeline drugs in Brain metastases pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Brain metastases: Understanding

Brain metastases: Overview

Brain metastases are a common complication of cancer and the most common type of brain tumor. Anywhere from 10% to 26% of patients who die from their cancer will develop brain metastases. While few cancers that metastasize to the brain can be cured using conventional therapies, long-term survival and palliation are possible with minimal adverse effects to patients. Increasingly, neuro-cognition and quality of life are being recognized as important endpoints for patients as survival continues to increase.

Brain metastases are the most common type of intracranial tumor. In the United States, an estimated 98,000 to 170,000 cases occur each year. The incidence of brain metastases is increasingly likely as a result of several factors. Patients with a systemic metastatic disease have a longer survival with new systemic therapies (including immunotherapy) that have recently seen more widespread use. Furthermore, the growing use of sensitive magnetic resonance imaging (MRI) techniques has contributed to the better detection of small asymptomatic brain metastases.

Pathophysiology
Metastatic cancer passes through the bloodstream and enters the central nervous system through a breakdown of the blood-brain barrier. Clonal cells then proliferate, causing local invasion, displacement, inflammation, and edema. Distribution throughout the central nervous system is more common in areas of high blood flow; however, different histological subtypes tend to have different distributions of location within the brain
Diagnosis
A head computed tomogram (CT) allows for a quick examination, although fine-slice MR of the brain with contrast is the gold standard for neuroimaging in cases of suspected brain metastases. MR allows for a determination of the number and anatomical location of tumors and the degree of associated edema. Basic laboratory assessment including complete blood count, metabolic panel, and liver function test should be performed.

Treatment
Metastatic breast cancer in any part of the body is usually treated with systemic medicines, which treat cancer throughout the entire body. For brain metastasis, local treatments that specifically target the brain, such as surgery or radiation, are sometimes recommended. Additionally, chemotherapy, immunotherapy, hormonal therapy, and targeted therapy could be used.

Brain metastases- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Brain metastases pipeline landscape is provided which includes the disease overview and Brain metastases treatment guidelines. The assessment part of the report embraces, in depth Brain metastases commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Brain metastases collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Brain metastases R&D. The therapies under development are focused on novel approaches to treat/improve Brain metastases.

Brain metastases Emerging Drugs Chapters

This segment of the Brain metastases report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Brain metastases Emerging Drugs

ANG1005: Angiochem
ANG1005 is a novel targeted taxane derivative that is the first oncology product to leverage Angiochem’s technology platform to cross the blood-brain barrier (BBB) and enter cancer cells. ANG1005 is an Angiopep-2 paclitaxel conjugate that gains entry into the brain by targeting the LRP-1, which is one of the most highly-expressed receptors on the surface of the BBB. Once inside the brain, ANG1005 enters tumor cells using the same receptor-mediated pathway through LRP-1, which is upregulated in various cancer cells including malignant glioma and metastatic cancers in the brain.

A Phase II, multi-center, open label study has been conducted with ANG1005 in patients with brain metastases from breast cancer (NCT01480583). The anticancer activity of ANG1005 was extremely encouraging and 2 additional Phase II trials have been conducted to further confirm its clinical activity in patients with recurrent high grade glioma (NCT01967810) and breast cancer patients with recurrent brain metastases (NCT02048059) and the drug is currently investigated in Phase III trials.

Azeliragon: Cantex Pharmaceuticals, Inc.

Azeliragon, is an oral, small molecule, administered once-daily, that inhibits RAGE interactions with its natural ligands, including HMGB1 and S100 proteins, in the tumor microenvironment. Activation of RAGE by these ligands stimulates cancer and its progression and metastasis and resistance to cancer treatment.

Azeliragon was licensed in mid-2021 from vTv Therapeutics Inc. and was originally in development by vTv for Alzheimer’s disease. There has been extensive demonstration of pre-clinical efficacy of RAGE inhibition in animal models of several cancers, including pancreatic cancer, glioblastoma, and brain metastasis from breast and lung cancer, as well as diverse serious complications of cancer, including cancer-related cognitive decline, as well as the development of metastatic disease. The drug is currently investigated in Phase I/II clinical trials for brain metastases.

AZD3759: Alpha Biopharma Ltd.

Zorifertinib (AZD3759) is a type of reversible new generation EGFR TKI, which has a strong ability to penetrate the bloodstream, cerebrospinal fluid, and can reach blood volume in the tissue. It is currently investigated for brain metastases and completed Phase II/III trial in July 2022.

Brain metastases: Therapeutic Assessment

This segment of the report provides insights about the different Brain metastases drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Brain metastases

There are approx. 45+ key companies which are developing the therapies for Brain metastases. The companies which have their Brain metastases drug candidates in the most advanced stage, i.e. phase III.

Phases

This report covers around 45+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Brain metastases pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Brain metastases: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Brain metastases therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Brain metastases drugs.

Brain metastases Report Insights

• Brain metastases Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Brain metastases Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Brain metastases drugs?
• How many Brain metastases drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Brain metastases?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Brain metastases therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Brain metastases and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• HUYA Bioscience International, LLC
• Angiochem
• Cantex Pharmaceuticals, Inc.
• Bristol-Myers Squibb
• Immuno Chem Therapeutics,LLC
• Kazia Therapeutics
• Alpha Biopharma Ltd
• Betta Pharmaceuticals Co., Ltd.
• TYK Medicines, Inc
• Bio Mimetix JV,LLC
• Amgen
• Jubilant Therapeutics
• Quadriga Biosciences, Inc.
• Pfizer
• Medolution Ltd.
• Puma Biotechnology, Inc.
• Seagen Inc.
• Jiangsu Hansoh Pharmaceutical Co., Ltd.
• ABM Therapeutics Corporation

Key Products

• HBI-8000
• ANG1005
• Azeliragon
• Nivolumab
• MW151
• Paxalisib
• AZD3759
• Icotinib
• TY-9591
• BMX-001
• AMG 510
• JBI-2174
• QBS72S
• Palbociclib
• Keynatinib
• HKI-272
• Tucatinib
• Almonertinib
• ABM-168

This product will be delivered within 1-3 business days.